Hernán’s appointment comes at a pivotal moment as Takeda intensifies its focus on advancing sustainable, value-based ...

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

First Devices Customized for a Plasma-Derived Therapy in Takeda’s Broad and Differentiated Portfolio Reflect Company’s Commitment to Providing a Patient-Centric Ecosystem of Support Takeda ...

DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2025 financial and ...

Proteus Syndrome Market Insight, Epidemiology and Market Forecast - 2034The Proteus Syndrome market is entering a pivotal decade, driven by ...

Takeda Pharmaceutical (TAK) said Monday it has received 510 (k) clearance for its HyHub and HyHub Duo PREMIUM Upgrade to read ...

DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement in early intervention for multiple myeloma ...

Co-authors reported grants from Takeda Pharmaceuticals and UCB, consulting for GlaxoSmithKline, and personal fees from the ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Organon & Co stands tenth on our list and has expanded in ...

Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

Thanks to a well-timed capital raising ahead of a major setback, Percheron lives on. Can it capitalise on a promising new asset?